The human lens after 48 weeks of treatment with lovastatin.

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

tenofovir alafenamide.

Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia.

Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.

Treatment with metronidazole of 48 patients with serious anaerobic infections.

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

tenofovir disoproxil fumarate-based single-tablet regimens.

Clinical experience with lovastatin.

Lovastatin rescues human and mice cartilage disorders.

Lovastatin-Mediated Changes in Human Tendon Cells.

The effect of two weeks of treatment with dutasteride on bleeding after transurethral resection of the prostate.

Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.

lovastatin.

The lens after renal transplantation.

Prevention of restenosis by lovastatin after successful coronary angioplasty.

Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.

Efficacy and safety of the adjustable gastric band - pooled interim analysis of the APEX and HERO studies at 48 weeks.

Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.

Lovastatin treatment of hypercholesterolemia in renal transplant recipients.

Predictive Factors for Delivery within 7 Days after Successful 48-Hour Treatment of Threatened Preterm Labor.

Lack of hypotension with lovastatin and pravastatin.

Pneumoperitoneum 48 days after laparoscopic hysterectomy.

Suggest Documents

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

tenofovir alafenamide.

Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia.

Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.

Treatment with metronidazole of 48 patients with serious anaerobic infections.

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.

tenofovir disoproxil fumarate-based single-tablet regimens.

Clinical experience with lovastatin.

Lovastatin rescues human and mice cartilage disorders.

Lovastatin-Mediated Changes in Human Tendon Cells.

The effect of two weeks of treatment with dutasteride on bleeding after transurethral resection of the prostate.

Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.

lovastatin.

The lens after renal transplantation.

Prevention of restenosis by lovastatin after successful coronary angioplasty.

Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.

Efficacy and safety of the adjustable gastric band - pooled interim analysis of the APEX and HERO studies at 48 weeks.

Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.

Lovastatin treatment of hypercholesterolemia in renal transplant recipients.

Predictive Factors for Delivery within 7 Days after Successful 48-Hour Treatment of Threatened Preterm Labor.

Lack of hypotension with lovastatin and pravastatin.

Pneumoperitoneum 48 days after laparoscopic hysterectomy.

The human lens after 48 weeks of treatment with lovastatin.

Recommend Documents

Follow Us